Premium
Mannose‐binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy
Author(s) -
Frakking F.N.J.,
Israëls J.,
Kremer L.C.M.,
Kuijpers T.W.,
Caron H.N.,
van de Wetering M.D.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22901
Subject(s) - medicine , mannan binding lectin , febrile neutropenia , neutropenia , bacteremia , pediatric cancer , pneumonia , immunology , sepsis , chemotherapy , genotype , cancer , oncology , antibiotics , lectin , biochemistry , chemistry , gene , microbiology and biotechnology , biology
Background We determined whether mannose‐binding lectin (MBL) deficiency is associated with an increased risk of febrile neutropenia (FN) and/or infection in pediatric oncology patients. Procedure We systematically searched and reviewed all the literature on MBL and infections in children with cancer, identified from a literature search of Medline, Embase, and Central (1966–April 2010). We extracted information on the type of study, patient characteristics, definition of MBL deficiency, definition of infection and method of detection, follow‐up period and the results of the outcome in different groups. The validity of each study was assessed. Results Six cohort studies were retrieved, consisting of 581 children with leukemia (n = 2) or varying types of cancer (n = 4). Many different outcome definitions were used. In only one out of three genotype studies, variant MBL2 genotypes, as well as MBL levels <1,000 µg/L, were associated with an increased duration of FN. In one additional MBL level study the number of FN episodes, bacteremia and severe bacterial infection were increased in patients with MBL levels <100 µg/L as compared to those with MBL levels of 100–999 µg/L. Sepsis, pneumonia, viral infection, and fungal infection were not associated with either MBL levels or genotypes in any of the studies. Conclusions MBL deficiency could not be identified as an independent risk factor for FN or infection in pediatric oncology patients. A multicenter study of children with comparable chemotherapy regimens, relevant and equal outcome definitions and measuring both MBL levels and genotypes, will be required to avoid clinical and methodological inconsistencies. Pediatr Blood Cancer 2011;57:89–96. © 2010 Wiley‐Liss, Inc.